An Adaptive Design Study of MTX228

MTX228 has been identified as a medication that might allow the re-growth of insulin producing beta cells in people with Type 1 Diabetes. Promoting the re-growth of lost beta cells would be beneficial to people with Type 1 Diabetes because it would allow them to take less insulin by injection and would improve their overall blood sugar control while reducing the risk and rate of low blood sugars. This open-label dose selection study aims to determine the optimal dose ofMTX228 for use in a future phase IIb study. The purpose is to investigate the relative effectiveness of different doses of MTX228 and to select the most effective dose for further investigation in a phase 2b study.

NCT Number	NCT06474598
Lead Sponsor	University of Alberta
Conditions	Type 1 Diabetes Mellitus
Enrollment	24 participants
Start Date	2024-11-14
Primary Completion	2026-10 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-04-13